| http://www.w3.org/ns/prov#value | - Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C. Fat Redistribution: Redistribution/accumulation of body fat has been observed in patients receiving antiretroviral therapy.
|
